Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii

被引:36
作者
Alcaide, F
Calatayud, L
Santín, M
Martín, R
机构
[1] Hosp Univ Bellvitge, Microbiol Serv, Dept Microbiol, Lhospitalet De Llobregat 08907, Barcelona, Spain
[2] Hosp Univ Bellvitge, Dept Infect Dis, Lhospitalet De Llobregat 08907, Barcelona, Spain
关键词
D O I
10.1128/AAC.48.12.4562-4565.2004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Mycobacterium kansasii is one of the most pathogenic and frequent nontuberculous mycobacteria isolated from humans. Patients with adverse drug reactions, resistant isolates, or suboptimal response require alternative treatment regimens. One hundred forty-eight consecutive clinical isolates of M. kansasii were tested for antimicrobial susceptibilities by the BACTEC 460 system (NCCLS) with two different inoculation protocols, one conventional and one alternative. In the alternative protocol, the inoculum 12B vial was incubated until the growth index was between 250 and 500. Four conventional antimycobacterial drugs (isoniazid, rifampin, streptomycin, and ethambutol) were studied with standard critical concentrations. The in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, and moxifloxacin were determined by measuring radiometric MICs. All isolates tested were identified as M. kansasii genotype I and were resistant to isoniazid at a concentration of 0.4 mug/ml. One hundred twenty isolates (81.1%) were inhibited by 1 mug of isoniazid per ml. A high level of resistance to isoniazid (>10 mug/ml) was observed in six isolates (41.1%). Only five strains (3.4%) were resistant to rifampin (>1 mug/ml). All isolates studied were susceptible to streptomycin and ethambutol. The MICs at which 90% of the isolates were inhibited (in micrograms per milliliter) were as follows: linezolid, 1 (range, <0.25 to 2); telithromycin, greater than or equal to16 (range, 4 to greater than or equal to16); clarithromycin, 0.5 (range, less than or equal to0.03 to 1); levofloxacin, 0.12 (range, 0.12 to 0.25); and moxifloxacin, 0.06 (range, less than or equal to0.06 to 0.12). The susceptibility testing results with both inoculation protocols showed perfect correlation. In conclusion, all M. kansash isolates showed decreased susceptibility to isoniazid, but resistance to rifampin was infrequent. Quinolones, especially moxifloxacin, were the most active antimicrobial agents tested, followed by clarithromycin. Linezolid also showed good activity against these microorganisms, but telithromycin's in vitro activity was poor.
引用
收藏
页码:4562 / 4565
页数:4
相关论文
共 33 条
[1]  
AHN CH, 1987, AM REV RESPIR DIS, V135, P10
[2]   Heterogeneity and clonality among isolates of Mycobacterium kansasii: Implications for epidemiological and pathogenicity studies [J].
Alcaide, F ;
Richter, I ;
Bernasconi, C ;
Springer, B ;
Hagenau, C ;
SchulzeRobbecke, R ;
Tortoli, E ;
Martin, R ;
Bottger, EC ;
Telenti, A .
JOURNAL OF CLINICAL MICROBIOLOGY, 1997, 35 (08) :1959-1964
[3]  
[Anonymous], 1996, MMWR Weekly, V45, P921
[4]   Emergence of Mycobacterium kansasii as the leading mycobacterial pathogen isolated over a 20-year period at a midwestern veterans affairs hospital [J].
Bittner, MJ ;
Horowitz, EA ;
Safranek, TJ ;
Preheim, LC .
CLINICAL INFECTIOUS DISEASES, 1996, 22 (06) :1109-1110
[5]   Incidence and clinical implications of isolation of Mycobacterium kansasii:: Results of a 5-year, population-based study [J].
Bloch, KC ;
Zwerling, L ;
Pletcher, MJ ;
Hahn, JA ;
Gerberding, JL ;
Ostroff, SM ;
Vugia, DJ ;
Reingold, AL .
ANNALS OF INTERNAL MEDICINE, 1998, 129 (09) :698-+
[6]   ACTIVITIES OF CLARITHROMYCIN AGAINST 8 SLOWLY GROWING SPECIES OF NONTUBERCULOUS MYCOBACTERIA, DETERMINED BY USING A BROTH MICRODILUTION MIC SYSTEM [J].
BROWN, BA ;
WALLACE, RJ ;
ONYI, GO .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (09) :1987-1990
[7]   In vitro activity of linezolid against slowly growing nontuberculous mycobacteria [J].
Brown-Elliott, BA ;
Crist, CJ ;
Mann, LB ;
Wilson, RW ;
Wallace, RJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (05) :1736-1738
[8]   Epidemiological, clinical, and prognostic differences between the diseases caused by Mycobacterium kansasii and Mycobacterium tuberculosis in patients infected with human immunodeficiency virus:: A multicenter study [J].
Canueto-Quintero, J ;
Caballero-Granado, FJ ;
Herrero-Romero, M ;
Domínguez-Castellano, A ;
Martín-Rico, P ;
Verdú, EV ;
Santamaría, DS ;
Cerquera, RC ;
Torres-Tortosa, M .
CLINICAL INFECTIOUS DISEASES, 2003, 37 (04) :584-590
[9]  
Chobot S, 1997, Cent Eur J Public Health, V5, P164
[10]  
DIAZ JCR, 2003, INT J ANTIMICROB AG, V47, P416